TY - JOUR
T1 - School-based hpv immunization of young adolescents
T2 - Effects of two brief health interventions
AU - Rickert, Vaughn I.
AU - Auslander, Beth A.
AU - Cox, Dena S.
AU - Rosenthal, Susan L.
AU - Rupp, Richard E.
AU - Zimet, Gregory D.
N1 - Funding Information:
Dr. Rickert serves on the US. Advisory Board for Human Papillomavirus for Merck & Co, Inc. as well as on the Merck & Co., Inc. Speaker’s Bureau. In addition, Dr. Rickert previously served on the Adolescent Health and Wellness Advisory Boards for Pfizer, Inc. and is a member of the Speaker’s Bureau. Drs. Auslander, Rosenthal, Rupp, and Cox have no current financial disclosures, but acknowledge that they each have been investigators on investigator initiated studies funded by Merck & Company, Inc. within the last 5 years. Dr. Zimet is an investigator on an investigator initiated study funded by Merck & Company, Inc. and has received an unrestricted program development grant from GlaxoSmithKline.
Funding Information:
This study was supported Merck & Co., Inc. through a grant (IISP #37286) and a grant from Health and Human Services Administration (T71MC0008) to the first author. Its contents are the sole responsibility of the authors and do not reflect the official view of Merck and Company, Inc., or the US. Department of Health and Human Services. These data were presented in part at the Pediatric Academic Societies annual meeting in Vancouver, British Columbia in May 2014.
Publisher Copyright:
© 2015 Taylor & Francis Group, LLC.
PY - 2015
Y1 - 2015
N2 - Adolescent immunization rates for human papillomavirus (HPV) are low and interventions within school-based health centers (SBHCs) may increase HPV uptake and series completion. We examined the effect of a parent health message intervention on HPV vaccination intent, first dose uptake and series completion among adolescents who received care at SBHCs. Via computer-assisted telephone interviews (CATI), 445 parents of young adolescents were randomly assigned to 2 two-level interventions using a 2 × 2 design (rhetorical question (RQ) or no-RQ and one-sided or two-sided message). The RQ intervention involved asking the parent a question they were likely to endorse (e.g., “Do you want to protect your daughter from cervical cancer?”) with the expectation that they would then behave in a manner consistent with their endorsement (i.e., agree to vaccinate). For the one-sided message, parents were given information that emphasized the safety and effectiveness of HPV vaccine, whereas the two-sided message acknowledged that some parents might have concerns about the vaccine, followed by reassurance regarding the safety and effectiveness. At CATI conclusion, parents indicated intentions to have their adolescents vaccinated. Parents who endorsed any intent were sent a consent form to return and all adolescents with signed returned consents were vaccinated at SBHCs. Medical records were reviewed for uptake/completion. Parents were 87% female; adolescents were 66% male and racially/ethnically diverse. 42.5% of parents indicated some intention to immunize, 51.4% were unsure, and 6.1% were not interested. 34% (n = 151) of adolescents received their first dose with series completion rates of 67% (n = 101). The RQ component of the intervention increased intention to vaccinate (RR = 1.45; 95%CI 1.16,1.81), but not first dose uptake or series completion. The 1-sided and 2-sided messages had no effect. This brief, RQ health intervention enhanced intent, but did not impact vaccination rates, likely due to the time delay between the intervention and consent form receipt.
AB - Adolescent immunization rates for human papillomavirus (HPV) are low and interventions within school-based health centers (SBHCs) may increase HPV uptake and series completion. We examined the effect of a parent health message intervention on HPV vaccination intent, first dose uptake and series completion among adolescents who received care at SBHCs. Via computer-assisted telephone interviews (CATI), 445 parents of young adolescents were randomly assigned to 2 two-level interventions using a 2 × 2 design (rhetorical question (RQ) or no-RQ and one-sided or two-sided message). The RQ intervention involved asking the parent a question they were likely to endorse (e.g., “Do you want to protect your daughter from cervical cancer?”) with the expectation that they would then behave in a manner consistent with their endorsement (i.e., agree to vaccinate). For the one-sided message, parents were given information that emphasized the safety and effectiveness of HPV vaccine, whereas the two-sided message acknowledged that some parents might have concerns about the vaccine, followed by reassurance regarding the safety and effectiveness. At CATI conclusion, parents indicated intentions to have their adolescents vaccinated. Parents who endorsed any intent were sent a consent form to return and all adolescents with signed returned consents were vaccinated at SBHCs. Medical records were reviewed for uptake/completion. Parents were 87% female; adolescents were 66% male and racially/ethnically diverse. 42.5% of parents indicated some intention to immunize, 51.4% were unsure, and 6.1% were not interested. 34% (n = 151) of adolescents received their first dose with series completion rates of 67% (n = 101). The RQ component of the intervention increased intention to vaccinate (RR = 1.45; 95%CI 1.16,1.81), but not first dose uptake or series completion. The 1-sided and 2-sided messages had no effect. This brief, RQ health intervention enhanced intent, but did not impact vaccination rates, likely due to the time delay between the intervention and consent form receipt.
KW - Brief health messages
KW - HPV vaccination
KW - Immunization
KW - Intervention
KW - SBHC
UR - http://www.scopus.com/inward/record.url?scp=84929070227&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84929070227&partnerID=8YFLogxK
U2 - 10.1080/21645515.2014.1004022
DO - 10.1080/21645515.2014.1004022
M3 - Article
C2 - 25692717
AN - SCOPUS:84929070227
VL - 11
SP - 315
EP - 321
JO - Human Vaccines and Immunotherapeutics
JF - Human Vaccines and Immunotherapeutics
SN - 2164-5515
IS - 2
ER -